Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 613

1.

Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutation.

Contant CM, Menke-Pluijmers MB, Seynaeve C, Meijers-Heijboer EJ, Klijn JG, Verhoog LC, Tjong Joe Wai R, Eggermont AM, van Geel AN.

Eur J Surg Oncol. 2002 Sep;28(6):627-32.

PMID:
12359199
2.

Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic.

Heemskerk-Gerritsen BA, Brekelmans CT, Menke-Pluymers MB, van Geel AN, Tilanus-Linthorst MM, Bartels CC, Tan M, Meijers-Heijboer HE, Klijn JG, Seynaeve C.

Ann Surg Oncol. 2007 Dec;14(12):3335-44. Epub 2007 May 31.

3.
4.

Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.

Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C, Strong L, Arun B.

Cancer. 2006 Dec 15;107(12):2745-51.

5.

Histopathological findings and follow-up after prophylactic mastectomy and immediate breast reconstruction in 100 women from families with hereditary breast cancer.

Isern AE, Loman N, Malina J, Olsson H, Ringberg A.

Eur J Surg Oncol. 2008 Oct;34(10):1148-54. doi: 10.1016/j.ejso.2008.03.002. Epub 2008 Apr 23.

PMID:
18434071
6.

Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.

Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van 't Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, Daly MB, Olopade OI, Weber BL.

J Clin Oncol. 2004 Mar 15;22(6):1055-62. Epub 2004 Feb 23.

PMID:
14981104
8.

Prophylactic surgery for women at high risk for breast cancer.

Blanchard DK, Hartmann LC.

Clin Breast Cancer. 2000 Jul;1(2):127-34; discussion 135. Review.

PMID:
11899651
9.

Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.

Meijers-Heijboer H, Brekelmans CT, Menke-Pluymers M, Seynaeve C, Baalbergen A, Burger C, Crepin E, van den Ouweland AW, van Geel B, Klijn JG.

J Clin Oncol. 2003 May 1;21(9):1675-81.

PMID:
12721241
10.

Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.

Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL; Prevention and Observation of Surgical End Points Study Group.

N Engl J Med. 2002 May 23;346(21):1616-22. Epub 2002 May 20.

11.

Breast cancer and ovarian cancer genetics.

Edlich RF, Winters KL, Lin KY.

J Long Term Eff Med Implants. 2005;15(5):533-45. Review.

PMID:
16218901
12.

Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting.

Morgan D, Sylvester H, Lucas FL, Miesfeldt S.

Fam Cancer. 2009;8(4):277-87. doi: 10.1007/s10689-009-9242-z. Epub 2009 Apr 4.

PMID:
19347608
13.

Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.

Kuschel B, Lux MP, Goecke TO, Beckmann MW.

Eur J Cancer Prev. 2000 Jun;9(3):139-50. Review.

PMID:
10954253
14.

Clinical, pathological and genetic features of women at high familial risk of breast cancer undergoing prophylactic mastectomy.

Scott CI, Iorgulescu DG, Thorne HJ, Henderson MA, Phillips KA; Kathleen Cuningham Foundation Consortium for Familial Breast Cancer (kConFab).

Clin Genet. 2003 Aug;64(2):111-21.

PMID:
12859406
15.

Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers.

Hartmann LC, Sellers TA, Schaid DJ, Frank TS, Soderberg CL, Sitta DL, Frost MH, Grant CS, Donohue JH, Woods JE, McDonnell SK, Vockley CW, Deffenbaugh A, Couch FJ, Jenkins RB.

J Natl Cancer Inst. 2001 Nov 7;93(21):1633-7.

PMID:
11698567
16.

Prophylactic mastectomy: why and when?

von Smitten K.

J Br Menopause Soc. 2003 Dec;9(4):151-5. Review.

PMID:
15107257
17.

Prophylactic mastectomy: the Rotterdam experience.

van Geel AN.

Breast. 2003 Dec;12(6):357-61.

PMID:
14659105
18.

The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.

Metcalfe KA, Lynch HT, Ghadirian P, Tung N, Olivotto IA, Foulkes WD, Warner E, Olopade O, Eisen A, Weber B, McLennan J, Sun P, Narod SA.

Gynecol Oncol. 2005 Jan;96(1):222-6.

PMID:
15589605
19.

Frequency of BRCA1/BRCA2 mutations in a population-based sample of young breast carcinoma cases.

Malone KE, Daling JR, Neal C, Suter NM, O'Brien C, Cushing-Haugen K, Jonasdottir TJ, Thompson JD, Ostrander EA.

Cancer. 2000 Mar 15;88(6):1393-402.

PMID:
10717622
20.

Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.

Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, Bartels CC, Verhoog LC, van den Ouweland AM, Niermeijer MF, Brekelmans CT, Klijn JG.

N Engl J Med. 2001 Jul 19;345(3):159-64.

Supplemental Content

Support Center